- Home
- KALV vs IBCP Comparison
KALV vs IBCP Comparison
Compare KALV & IBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- IBCP
- Stock Information
- Founded
- KALV N/A
- IBCP 1864
- Country
- KALV United States
- IBCP United States
- Employees
- KALV N/A
- IBCP N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- IBCP Major Banks
- Sector
- KALV Health Care
- IBCP Finance
- Exchange
- KALV Nasdaq
- IBCP Nasdaq
- Market Cap
- KALV 637.9M
- IBCP 681.1M
- IPO Year
- KALV N/A
- IBCP N/A
- Fundamental
- Price
- KALV $15.82
- IBCP $32.82
- Analyst Decision
- KALV Strong Buy
- IBCP Hold
- Analyst Count
- KALV 9
- IBCP 3
- Target Price
- KALV $26.29
- IBCP $36.00
- AVG Volume (30 Days)
- KALV 734.1K
- IBCP 89.0K
- Earning Date
- KALV 09-09-2025
- IBCP 10-23-2025
- Dividend Yield
- KALV N/A
- IBCP 3.17%
- EPS Growth
- KALV N/A
- IBCP N/A
- EPS
- KALV N/A
- IBCP 3.06
- Revenue
- KALV N/A
- IBCP $217,457,000.00
- Revenue This Year
- KALV N/A
- IBCP N/A
- Revenue Next Year
- KALV $221.95
- IBCP $5.90
- P/E Ratio
- KALV N/A
- IBCP $10.73
- Revenue Growth
- KALV N/A
- IBCP 2.56
- 52 Week Low
- KALV $7.30
- IBCP $26.75
- 52 Week High
- KALV $16.32
- IBCP $40.32
- Technical
- Relative Strength Index (RSI)
- KALV 71.16
- IBCP 55.72
- Support Level
- KALV $13.72
- IBCP $31.01
- Resistance Level
- KALV $13.96
- IBCP $33.37
- Average True Range (ATR)
- KALV 0.69
- IBCP 0.63
- MACD
- KALV 0.31
- IBCP 0.13
- Stochastic Oscillator
- KALV 99.15
- IBCP 74.22
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.